SG Americas Securities
TRVI icon

SG Americas Securities’s Trevi Therapeutics TRVI Stock Holding History

SG Americas Securities’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Sell
28,051
-96,511
-77% -$1.08M ﹤0.01% 2400
2025
Q4 		$1.56M Buy
124,562
+60,017
+93% +$694K ﹤0.01% 1689
2025
Q3 		$591K Buy
+64,545
New +$484K ﹤0.01% 1975
2025
Q2 		– Sell
-24,661
Closed -$155K – 3599
2025
Q1 		$155K Sell
24,661
-2,131
-8% -$10.2K ﹤0.01% 2723
2024
Q4 		$110K Buy
26,792
+3,387
+14% +$10.8K ﹤0.01% 2674
2024
Q3 		$78K Buy
+23,405
New +$69.6K ﹤0.01% 3144
2024
Q2 		– Sell
-14,592
Closed -$50K – 3315
2024
Q1 		$50K Sell
14,592
-83,661
-85% -$187K ﹤0.01% 2769
2023
Q4 		$132K Buy
98,253
+78,656
+401% +$119K ﹤0.01% 2525
2023
Q3 		$43K Buy
+19,597
New +$44.3K ﹤0.01% 2972

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return